Ironwood Pharmaceuticals, Inc. clinical trials

Also known as Microbia.

The registry lists 45 studies whose lead sponsor is Ironwood Pharmaceuticals, Inc. or one of 2 companies grouped under it. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 4, 2026.

Studies

Recruiting first, then most recently updated. Showing 45 of 45.

• A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)RecruitingNCT07742735Phase 3

  Sponsor listed in the registry: VectivBio AG · First submitted after VectivBio AG became part of Ironwood Pharmaceuticals, Inc.

• Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)TerminatedNCT05415410Phase 2

  Sponsor listed in the registry: VectivBio AG · First submitted before VectivBio AG became part of Ironwood Pharmaceuticals, Inc.

• A Phase 1 Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic FunctionCompletedNCT05706623Phase 1

  Sponsor listed in the registry: VectivBio AG · First submitted before VectivBio AG became part of Ironwood Pharmaceuticals, Inc.

• Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.Active, not recruitingNCT05018286Phase 3

  Sponsor listed in the registry: VectivBio AG · First submitted before VectivBio AG became part of Ironwood Pharmaceuticals, Inc.

• Metabolic Balance Study of Apraglutide in Patients With Short Bowel Syndrome, Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC)CompletedNCT04964986Phase 2

  Sponsor listed in the registry: VectivBio AG · First submitted before VectivBio AG became part of Ironwood Pharmaceuticals, Inc.

• A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain SyndromeTerminatedNCT05740007Phase 2
• Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IFCompletedNCT04627025Phase 3

  Sponsor listed in the registry: VectivBio AG · First submitted before VectivBio AG became part of Ironwood Pharmaceuticals, Inc.

• Relative Bioavailability of a New Presentation of Apraglutide Versus the Reference FormulationCompletedNCT06002555Phase 1

  Sponsor listed in the registry: VectivBio AG · First submitted after VectivBio AG became part of Ironwood Pharmaceuticals, Inc.

• Study of Pharmacokinetics and Safety of Apraglutide in Participants With Normal and Impaired Kidney Function.CompletedNCT04699032Phase 1

  Sponsor listed in the registry: VectivBio AG · First submitted before VectivBio AG became part of Ironwood Pharmaceuticals, Inc.

• Evaluation of Apraglutide on Gastric EmptyingCompletedNCT05995704Phase 1

  Sponsor listed in the registry: VectivBio AG · First submitted before VectivBio AG became part of Ironwood Pharmaceuticals, Inc.

• A Study of Multiple-ascending Doses of IW-3300 in Healthy SubjectsCompletedNCT05362695Phase 1
• A Study of Single Ascending Doses of IW-3300 in Healthy VolunteersCompletedNCT05188261Phase 1
• A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD)CompletedNCT03285178Phase 2

  Sponsor listed in the registry: Cyclerion Therapeutics · First submitted before Cyclerion Therapeutics left Ironwood Pharmaceuticals, Inc.

• Study to Evaluate Efficacy and Safety of IW-6118 in Patients Undergoing Third Molar ExtractionCompletedNCT01107236Phase 2
• A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)TerminatedNCT02837783Phase 4
• A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal ImpairmentTerminatedNCT03226899Phase 4
• A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)TerminatedNCT03561090Phase 3
• Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)CompletedNCT03561883Phase 3
• Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II AchalasiaTerminatedNCT02931565Phase 2

  Sponsor listed in the registry: Cyclerion Therapeutics · First submitted before Cyclerion Therapeutics left Ironwood Pharmaceuticals, Inc.

• A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel SyndromeCompletedNCT03931785Phase 2
• A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)CompletedNCT03573908Phase 3
• Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and HypertensionCompletedNCT03091920Phase 2

  Sponsor listed in the registry: Cyclerion Therapeutics · First submitted before Cyclerion Therapeutics left Ironwood Pharmaceuticals, Inc.

• Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)CompletedNCT02559206Phase 2
• A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and HypertensionCompletedNCT02906579Phase 2

  Sponsor listed in the registry: Cyclerion Therapeutics · First submitted before Cyclerion Therapeutics left Ironwood Pharmaceuticals, Inc.

• A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)CompletedNCT02637557Phase 2
• Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult VolunteersCompletedNCT03856970Phase 1
• A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator, Olinciguat (IW-1701), in Healthy VolunteersCompletedNCT03892499Phase 1

  Sponsor listed in the registry: Cyclerion Therapeutics · First submitted before Cyclerion Therapeutics left Ironwood Pharmaceuticals, Inc.

• A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Praliciguat in Healthy Male VolunteersCompletedNCT03818295Phase 1

  Sponsor listed in the registry: Cyclerion Therapeutics · First submitted before Cyclerion Therapeutics left Ironwood Pharmaceuticals, Inc.

• A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Olinciguat in Healthy Male VolunteersCompletedNCT03795519Phase 1

  Sponsor listed in the registry: Cyclerion Therapeutics · First submitted before Cyclerion Therapeutics left Ironwood Pharmaceuticals, Inc.

• Trial of IW-1701 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy VolunteersCompletedNCT02572349Phase 1

  Sponsor listed in the registry: Cyclerion Therapeutics · First submitted before Cyclerion Therapeutics left Ironwood Pharmaceuticals, Inc.

• A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of Praliciguat (IW-1973) in Healthy VolunteersCompletedNCT03499106Phase 1

  Sponsor listed in the registry: Cyclerion Therapeutics · First submitted before Cyclerion Therapeutics left Ironwood Pharmaceuticals, Inc.

• Trial of IW-1973 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy VolunteersCompletedNCT02616861Phase 1

  Sponsor listed in the registry: Cyclerion Therapeutics · First submitted before Cyclerion Therapeutics left Ironwood Pharmaceuticals, Inc.

• A Trial of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Healthy SubjectsCompletedNCT02792998Phase 1

  Sponsor listed in the registry: Cyclerion Therapeutics · First submitted before Cyclerion Therapeutics left Ironwood Pharmaceuticals, Inc.

• An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With ConstipationCompletedNCT00730171Phase 3
• Trial of Linaclotide in Patients With Chronic Idiopathic ConstipationCompletedNCT02291679Phase 3
• Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)CompletedNCT02289846Phase 2
• Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump InhibitorsCompletedNCT02030925Phase 2
• Phase 2a Study of IW-9179 to Treat Functional DyspepsiaTerminatedNCT01712412Phase 2
• Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)CompletedNCT00938717Phase 3
• Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic ConstipationCompletedNCT00402337Phase 2
• Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)CompletedNCT00460811Phase 2
• Trial of Linaclotide in Patients With Chronic ConstipationCompletedNCT00730015Phase 3
• Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic ConstipationCompletedNCT00306748Phase 2
• Study of Oral MD-0727 Administered to Patients With Primary HypercholesterolemiaCompletedNCT00404001Phase 2
• Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBSCompletedNCT00258193Phase 2